ProfileGDS5678 / 1426763_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 90% 89% 89% 89% 87% 88% 86% 87% 87% 88% 88% 87% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6582287
GSM967853U87-EV human glioblastoma xenograft - Control 27.1660990
GSM967854U87-EV human glioblastoma xenograft - Control 37.0944989
GSM967855U87-EV human glioblastoma xenograft - Control 47.1599289
GSM967856U87-EV human glioblastoma xenograft - Control 57.0171289
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4414787
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.6997988
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.5290586
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6638587
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6675687
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.7507488
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8662188
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.7109287
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.6683287